Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1995 May;115(1):84–94. doi: 10.1111/j.1476-5381.1995.tb16324.x

The anti-emetic effects of CP-99,994 in the ferret and the dog: role of the NK1 receptor.

J W Watson 1, S F Gonsalves 1, A A Fossa 1, S McLean 1, T Seeger 1, S Obach 1, P L Andrews 1
PMCID: PMC1908747  PMID: 7544198

Abstract

1. The selective NK1 receptor antagonist, CP-99,994, produced dose-related (0.1-1.0 mg kg-1, s.c.) inhibition of vomiting and retching in ferrets challenged with central (loperamide and apomorphine), peripheral (CuSO4) and mixed central and peripheral (ipecac, cisplatin) emetic stimuli. 2. Parallel studies with the enantiomer, CP-100,263 (1 mg kg-1, s.c.), which is > 1,000 fold less potent as a NK1 antagonist, indicated that it was without significant effect against CuSO4, loperamide, cisplatin and apomorphine-induced emesis. Against ipecac, it inhibited both retching and vomiting, expressing approximately 1/10th the potency of CP-99,994. 3. The 5-HT3 receptor antagonist, tropisetron (1 mg kg-1, s.c.) inhibited retching and vomiting to cisplatin and ipecac, but not CuSO4 or loperamide. 4. CP-99,994 (1 mg kg-1, i.v.) blocked retching induced by electrical stimulation of the ventral abdominal vagus without affecting the cardiovascular response, the apnoeic response to central vagal stimulation or the guarding and hypertensive response to stimulation of the greater splanchnic nerves. CP-99,994 (1 mg kg-1, i.v.) did not alter baseline cardiovascular and respiratory parameters and it failed to block the characteristic heart rate, blood pressure and respiratory rate/depth changes in response to i.v. 2-methyl-5-HT challenge (von Bezold-Jarisch reflex). 5. Using in vitro autoradiography, [3H]-substance P was shown to bind to several regions of the ferret brainstem with the density of binding in the nucleus tractus solitarius being much greater than in the area postrema. This binding was displaced by CP-99,994 in a concentration-related manner. 6. In dogs, CP-99,994 (40 micrograms kg-1 bolus and 300 micrograms kg-1 h-1, i.v.) produced statistically significant reductions in vomiting to CuSO4 and apomorphine as well as retching to CuSO4. 7. Together, these studies support the hypothesis that the NK1 receptor antagonist properties of CP-99,994 are responsible for its broad spectrum anti-emetic effects. They also suggest that CP-99,994 acts within the brainstem, most probably within the nucleus tractus solitarius although the involvement of the area postrema could not be excluded.

Full text

PDF
84

Images in this article

91Figure 4
on p.91

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aapro M. S. 5-HT3 receptor antagonists. An overview of their present status and future potential in cancer therapy-induced emesis. Drugs. 1991 Oct;42(4):551–568. doi: 10.2165/00003495-199142040-00002. [DOI] [PubMed] [Google Scholar]
  2. Andrews P. L., Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology. 1993 Aug;32(8):799–806. doi: 10.1016/0028-3908(93)90189-a. [DOI] [PubMed] [Google Scholar]
  3. Andrews P. L., Davis C. J., Bingham S., Davidson H. I., Hawthorn J., Maskell L. The abdominal visceral innervation and the emetic reflex: pathways, pharmacology, and plasticity. Can J Physiol Pharmacol. 1990 Feb;68(2):325–345. doi: 10.1139/y90-047. [DOI] [PubMed] [Google Scholar]
  4. Andrews P. L., Rapeport W. G., Sanger G. J. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci. 1988 Sep;9(9):334–341. doi: 10.1016/0165-6147(88)90106-x. [DOI] [PubMed] [Google Scholar]
  5. Andrews P. L. Vagal afferent innervation of the gastrointestinal tract. Prog Brain Res. 1986;67:65–86. doi: 10.1016/s0079-6123(08)62757-0. [DOI] [PubMed] [Google Scholar]
  6. Armstrong D. M., Pickel V. M., Joh T. H., Reis D. J., Miller R. J. Immunocytochemical localization of catecholamine synthesizing enzymes and neuropeptides in area postrema and medial nucleus tractus solitarius of rat brain. J Comp Neurol. 1981 Mar 1;196(3):505–517. doi: 10.1002/cne.901960312. [DOI] [PubMed] [Google Scholar]
  7. Armstrong D. M., Pickel V. M., Reis D. J. Electron microscopic immunocytochemical localization of substance P in the area postrema of rat. Brain Res. 1982 Jul 8;243(1):141–146. doi: 10.1016/0006-8993(82)91127-1. [DOI] [PubMed] [Google Scholar]
  8. BORISON H. L., WANG S. C. Physiology and pharmacology of vomiting. Pharmacol Rev. 1953 Jun;5(2):193–230. [PubMed] [Google Scholar]
  9. Bacon P. J., Brazier D. J., Smith R., Smith S. E. Cardiovascular responses to metipranolol and timolol eyedrops in healthy volunteers. Br J Clin Pharmacol. 1989 Jan;27(1):1–5. doi: 10.1111/j.1365-2125.1989.tb05327.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Barnes N. M., Bunce K. T., Naylor R. J., Rudd J. A. The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology. 1991 Oct;30(10):1073–1083. doi: 10.1016/0028-3908(91)90136-y. [DOI] [PubMed] [Google Scholar]
  11. Baude A., Lanoir J., Vernier P., Puizillout J. J. Substance P-immunoreactivity in the dorsal medial region of the medulla in the cat: effects of nodosectomy. J Chem Neuroanat. 1989 Mar-Apr;2(2):67–81. [PubMed] [Google Scholar]
  12. Bermudez J., Boyle E. A., Miner W. D., Sanger G. J. The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer. 1988 Nov;58(5):644–650. doi: 10.1038/bjc.1988.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bhandari P., Andrews P. L. Preliminary evidence for the involvement of the putative 5-HT4 receptor in zacopride- and copper sulphate-induced vomiting in the ferret. Eur J Pharmacol. 1991 Nov 12;204(3):273–280. doi: 10.1016/0014-2999(91)90852-h. [DOI] [PubMed] [Google Scholar]
  14. Bhandari P., Bingham S., Andrews P. L. The neuropharmacology of loperamide-induced emesis in the ferret: the role of the area postrema, vagus, opiate and 5-HT3 receptors. Neuropharmacology. 1992 Aug;31(8):735–742. doi: 10.1016/0028-3908(92)90034-m. [DOI] [PubMed] [Google Scholar]
  15. Bhandari P., Gupta Y. K., Seth S. D. BRL 43694, a new 5HT3 receptor antagonist, prevents cisplatin-induced emesis in dogs. Methods Find Exp Clin Pharmacol. 1989 May;11(5):361–363. [PubMed] [Google Scholar]
  16. Carpenter D. O., Briggs D. B., Strominger N. Peptide-induced emesis in dogs. Behav Brain Res. 1984 Mar;11(3):277–281. doi: 10.1016/0166-4328(84)90220-1. [DOI] [PubMed] [Google Scholar]
  17. Carpenter D. O., Briggs D. B., Strominger N. Responses of neurons of canine area postrema to neurotransmitters and peptides. Cell Mol Neurobiol. 1983 Jun;3(2):113–126. doi: 10.1007/BF00735276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Cordts R. E., Yochmowitz M. G., Hardy K. A. Evaluation of domperidone as a modifier of gamma-radiation-induced emesis. Int J Radiat Oncol Biol Phys. 1987 Sep;13(9):1333–1337. doi: 10.1016/0360-3016(87)90225-2. [DOI] [PubMed] [Google Scholar]
  19. Costall B., Domeney A. M., Naylor R. J., Owera-Atepo J. B., Rudd J. A., Tattersall F. D. Fluphenazine, ICS 205-930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology. 1990 May;29(5):453–462. doi: 10.1016/0028-3908(90)90167-p. [DOI] [PubMed] [Google Scholar]
  20. Diamant S., Eldar-Geva T., Atlas D. Imidazoline binding sites in human placenta: evidence for heterogeneity and a search for physiological function. Br J Pharmacol. 1992 May;106(1):101–108. doi: 10.1111/j.1476-5381.1992.tb14300.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Dockray G. J., Sharkey K. A. Neurochemistry of visceral afferent neurones. Prog Brain Res. 1986;67:133–148. doi: 10.1016/s0079-6123(08)62760-0. [DOI] [PubMed] [Google Scholar]
  22. Fukui H., Yamamoto M., Sato S. Vagal afferent fibers and peripheral 5-HT3 receptors mediate cisplatin-induced emesis in dogs. Jpn J Pharmacol. 1992 Jun;59(2):221–226. doi: 10.1254/jjp.59.221. [DOI] [PubMed] [Google Scholar]
  23. Gillis R. A., Helke C. J., Hamilton B. L., Norman W. P., Jacobowitz D. M. Evidence that substance P is a neurotransmitter of baro- and chemoreceptor afferents in nucleus tractus solitarius. Brain Res. 1980 Jan 13;181(2):476–481. doi: 10.1016/0006-8993(80)90633-2. [DOI] [PubMed] [Google Scholar]
  24. Higgins G. A., Kilpatrick G. J., Bunce K. T., Jones B. J., Tyers M. B. 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol. 1989 May;97(1):247–255. doi: 10.1111/j.1476-5381.1989.tb11948.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Knox A. P., Strominger N. L., Battles A. H., Carpenter D. O. Behavioral studies of emetic sensitivity in the ferret. Brain Res Bull. 1993;31(5):477–484. doi: 10.1016/0361-9230(93)90112-o. [DOI] [PubMed] [Google Scholar]
  26. Lang I. M., Marvig J. Functional localization of specific receptors mediating gastrointestinal motor correlates of vomiting. Am J Physiol. 1989 Jan;256(1 Pt 1):G92–G99. doi: 10.1152/ajpgi.1989.256.1.G92. [DOI] [PubMed] [Google Scholar]
  27. Lucot J. B., Crampton G. H. 8-OH-DPAT suppresses vomiting in the cat elicited by motion, cisplatin or xylazine. Pharmacol Biochem Behav. 1989 Jul;33(3):627–631. doi: 10.1016/0091-3057(89)90399-7. [DOI] [PubMed] [Google Scholar]
  28. Lundberg J., Ahlman H., Dahlström A., Kewenter J. Catecholamine-containing nerve fibres in the human abdominal vagus. Gastroenterology. 1976 Mar;70(3):472–474. [PubMed] [Google Scholar]
  29. Makale M. T., King G. L. Surgical and pharmacological dissociation of cardiovascular and emetic responses to intragastric CuSO4. Am J Physiol. 1992 Aug;263(2 Pt 2):R284–R291. doi: 10.1152/ajpregu.1992.263.2.R284. [DOI] [PubMed] [Google Scholar]
  30. McLean S., Ganong A., Seymour P. A., Snider R. M., Desai M. C., Rosen T., Bryce D. K., Longo K. P., Reynolds L. S., Robinson G. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor. J Pharmacol Exp Ther. 1993 Oct;267(1):472–479. [PubMed] [Google Scholar]
  31. Mifflin S. W. Laryngeal afferent inputs to the nucleus of the solitary tract. Am J Physiol. 1993 Aug;265(2 Pt 2):R269–R276. doi: 10.1152/ajpregu.1993.265.2.R269. [DOI] [PubMed] [Google Scholar]
  32. Milano S., Grélot L., Chen Z., Bianchi A. L. Vagal-induced vomiting in decerebrate cat is not suppressed by specific 5-HT3 receptor antagonists. J Auton Nerv Syst. 1990 Nov;31(2):109–118. doi: 10.1016/0165-1838(90)90067-s. [DOI] [PubMed] [Google Scholar]
  33. Miner W. D., Sanger G. J. Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol. 1986 Jul;88(3):497–499. doi: 10.1111/j.1476-5381.1986.tb10228.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Newton B. W., Maley B., Traurig H. The distribution of substance P, enkephalin, and serotonin immunoreactivities in the area postrema of the rat and cat. J Comp Neurol. 1985 Apr 1;234(1):87–104. doi: 10.1002/cne.902340107. [DOI] [PubMed] [Google Scholar]
  35. Payan D. G., Brewster D. R., Goetzl E. J. Stereospecific receptors for substance P on cultured human IM-9 lymphoblasts. J Immunol. 1984 Dec;133(6):3260–3265. [PubMed] [Google Scholar]
  36. Priestman T. J. Clinical studies with ondansetron in the control of radiation-induced emesis. Eur J Cancer Clin Oncol. 1989;25 (Suppl 1):S29–S33. [PubMed] [Google Scholar]
  37. Reynolds D. J., Barber N. A., Grahame-Smith D. G., Leslie R. A. Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res. 1991 Nov 29;565(2):231–236. doi: 10.1016/0006-8993(91)91654-j. [DOI] [PubMed] [Google Scholar]
  38. Ribas C., Miralles A., García-Sevilla J. A. Acceleration by chronic treatment with clorgyline of the turnover of brain alpha 2-adrenoceptors in normotensive but not in spontaneously hypertensive rats. Br J Pharmacol. 1993 Sep;110(1):99–106. doi: 10.1111/j.1476-5381.1993.tb13777.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Snider R. M., Constantine J. W., Lowe J. A., 3rd, Longo K. P., Lebel W. S., Woody H. A., Drozda S. E., Desai M. C., Vinick F. J., Spencer R. W. A potent nonpeptide antagonist of the substance P (NK1) receptor. Science. 1991 Jan 25;251(4992):435–437. doi: 10.1126/science.1703323. [DOI] [PubMed] [Google Scholar]
  40. Strominger N. L., Knox A. P., Carpenter D. O. The connectivity of the area postrema in the ferret. Brain Res Bull. 1994;33(1):33–47. doi: 10.1016/0361-9230(94)90047-7. [DOI] [PubMed] [Google Scholar]
  41. Tattersall F. D., Rycroft W., Hill R. G., Hargreaves R. J. Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology. 1994 Feb;33(2):259–260. doi: 10.1016/0028-3908(94)90018-3. [DOI] [PubMed] [Google Scholar]
  42. Thompson P. I., Bingham S., Andrews P. L., Patel N., Joel S. P., Slevin M. L. Morphine 6-glucuronide: a metabolite of morphine with greater emetic potency than morphine in the ferret. Br J Pharmacol. 1992 May;106(1):3–8. doi: 10.1111/j.1476-5381.1992.tb14284.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Yoshida N., Omoya H., Ito T. DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog. J Pharmacol Exp Ther. 1992 Mar;260(3):1159–1165. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES